Instituto Universitario de Investigación en Neuroquímica
Ikastegia/Institutua
![Foto de Instituto Universitario de Investigación en Neuroquímica](/img/uploaded/210288F0EBF11B5B400384EE1F7A6332.jpg)
![Foto de Hospital Universitario Reina Sofia](/img/noimage_org.png)
Hospital Universitario Reina Sofia
Córdoba, EspañaHospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (23)
2023
-
Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease
European Journal of Neurology, Vol. 30, Núm. 4, pp. 861-871
-
The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
Brain Sciences, Vol. 13, Núm. 9
2021
-
(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice
Pharmacological Research, Vol. 169
-
Gut microbiota, innate immune pathways, and inflammatory control mechanisms in patients with major depressive disorder
Translational Psychiatry, Vol. 11, Núm. 1
-
Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease
Molecules, Vol. 26, Núm. 11
-
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Molecular and Cellular Neuroscience, Vol. 110
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
2020
-
Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors
British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 4034-4054
2019
-
Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease
Molecules, Vol. 24, Núm. 15
-
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Translational Neurodegeneration, Vol. 8, Núm. 1
-
Structure–effect relationships of novel semi-synthetic cannabinoid derivatives
Frontiers in Pharmacology, Vol. 10
2018
-
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor
Journal of Neuroinflammation, Vol. 15, Núm. 1
-
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Biochemical Pharmacology, Vol. 157, pp. 217-226
-
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
British Journal of Pharmacology, Vol. 175, Núm. 19, pp. 3813-3831
2017
2016
-
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215
-
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
Scientific Reports, Vol. 6
-
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties
European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80
-
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease
Scientific Reports, Vol. 6
2015
-
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
Neurotherapeutics, Vol. 12, Núm. 1, pp. 185-199